A new rapid methodological strategy to assess BRCA mutational status

Molecular Biotechnology

Volumn 54, Issue 3, 2013, Pages 954-960

  Vuttariello, Emilia ^a   Borra, Marco ^b   Calise, Celeste ^a   Mauriello, Elvira ^b   Greggi, Stefano ^a   Vecchione, Aldo ^a   Biffali, Elio ^b   Chiappetta, Gennaro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b STAZIONE ZOOLOGICA ANTON DOHRN   (Italy)

Author keywords

BRCA1; BRCA2; Direct sequencing; Genetic testing; Hereditary breast and ovarian cancer (HBOC)

Indexed keywords

BRCA1; BRCA2; DIRECT SEQUENCING; GENETIC TESTING; OVARIAN CANCERS;

PATIENT TREATMENT; POLYMERASE CHAIN REACTION;

DISEASES;

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER SCREENING; CODING; FAMILIAL CANCER; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; OVARY CANCER; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 84882872712     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-012-9646-0     Document Type: Article

References (22)

1. Lux, M. P.; Fasching, P. A.; Beckmann, M. W. (2006). Hereditary breast and ovarian cancer: Review and future perspectives. Journal of Molecular Medicine, 84, 16-28.
2. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P. A.; Harshman, K.; Tavtigian, S.; et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
3. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-792.
4. Tai, Y. C.; Domchek, S.; Parmigiani, G.; Chen, S. (2007). Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute, 99, 1811-1814.
5. Welcsh, P. L.; King, M. C. (2001). BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human Molecular Genetics, 10, 705-713.
6. Pruthi, S.; Gostout, B. S.; Lindor, N. M. (2010). Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clinic Proceedings, 85, 1111-1120.
7. Turnbull, C.; Rahman, N. (2008). Genetic predisposition to breast cancer: Past, present, and future. Annual Review of Genomics and Human Genetics, 9, 321-345.
8. Banerjee, S. (2007). BRCA1 (breast cancer 1, early onset). Atlas of genetics and cytogenetics in oncology and haematology. http:// AtlasGeneticsOncology.org/Genes/BRCA1ID163ch17q21.html. Accessed 23 Jan 2012.
9. Starita, L. M.; Parvin, J. D. (2003). The multiple nuclear functions of BRCA1: Transcription, ubiquitination and DNA repair. Current Opinion in Cell Biology, 15, 345-350.
10. Patel, K. J.; Yu, V. P.; Lee, H.; Corcoran, A.; Thistlethwaite, F. C.; Evans, M. J.; et al. (1998). Involvement of Brca2 in DNA repair. Molecular Cell, 1, 347-357.
11. Van der Groep, P.; Van der Wall, E.; Van Diest, P. J. (2011). Pathology of hereditary breast cancer. Cellular Oncology, 34, 71-88.
12. Wang, Y.; Cortez, D.; Yazdi, P.; Neff, N.; Elledge, S. J.; Qin, J. (2000). BASC a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes & Development, 14, 927-939.
13. Holloman, W. K. (2011). Unraveling the mechanism of BRCA2 in homologous recombination. Nature Structural & Molecular Biology, 18, 748-754.
14. Annunziata, C.M.; Bates, S.E. (2010) PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biological Reports. 2, 10.doi: 10.3410/B2-10.
15. Telli, M. L.; Ford, J. M. (2010). PARP inhibitors in Breast Cancer. Clinical Advances in Hematology & Oncology: H&O, 8, 629-635.
16. Ferla, R.; Calò, V.; Cascio, S.; Rinaldi, G.; Badalamenti, G.; Carreca, I.; et al. (2007). Founder mutations in BRCA1 and BRCA2 genes. Annals of Oncology, 18, 93-98.
17. Phelan, C. M.; Dapic, V.; Tice, B.; Favis, R.; Kwan, E.; Barany, F.; et al. (2005). Classification of BRCA1 missense variants of unknown clinical significance. Journal of Medical Genetics, 42, 138-146.
18. Gerhardus, A.; Schleberger, H.; Schlegelberger, B.; Gadzicki, D. (2007). Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. European Journal of Human Genetics, 15, 619-627.
19. De Leeneer, K.; Coene, I.; Poppe, B.; De Paepe, A.; Claes, K. (2008). Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms. Clinical Chemistry, 54, 982-989.
20. Trainer, A. H.; Lewis, C. R.; Tucker, K.; Meiser, B.; Friedlander, M.; Ward, R. L. (2010). The role of BRCA mutation testing in determining breast cancer therapy. Nature Reviews. Clinical Oncology, 7, 708-717.
21. Rothberg, J. M.; Hinz, W.; Rearick, T. M.; Schultz, J.; Mileski, W.; Davey, M.; et al. (2011). An integrated semiconductor device enabling non-optical genome sequencing. Nature, 475, 348-352.
22. Glenn, T. C. (2011). Field guide to next-generation DNA sequencers. Molecular Ecology Resources, 11, 759-769.